Nektar Therapeutics' (NKTR) Market Perform Rating Reaffirmed at William Blair

William Blair reaffirmed their market perform rating on shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) in a research note released on Monday,RTT News reports. William Blair also issued estimates for Nektar Therapeutics' Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.78) EPS, Q1 2026 earnings at ($0.17) EPS, Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.19) EPS and FY2026 earnings at ($0.74) EPS.

NKTR has been the subject of a number of other research reports. HC Wainwright reaffirmed a "buy" rating and set a $6.50 price objective on shares of Nektar Therapeutics in a research report on Thursday, March 13th. Jefferies Financial Group raised Nektar Therapeutics from a "hold" rating to a "buy" rating and raised their price objective for the company from $1.00 to $2.00 in a research report on Friday, April 11th. Oppenheimer raised Nektar Therapeutics from a "market perform" rating to an "outperform" rating and set a $6.00 price objective for the company in a research report on Friday, March 14th. Finally, StockNews.com assumed coverage on Nektar Therapeutics in a research report on Wednesday, April 16th. They set a "hold" rating for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $4.50.

Nektar Therapeutics Trading Up 0.7%

Shares of NASDAQ NKTR traded up $0.01 during mid-day trading on Monday, hitting $0.69. The company had a trading volume of 1,429,703 shares, compared to its average volume of 1,841,044. Nektar Therapeutics has a 1 year low of $0.43 and a 1 year high of $1.81. The stock's 50-day moving average price is $0.70 and its 200-day moving average price is $0.89. The company has a market capitalization of $127.48 million, a price-to-earnings ratio of -0.82 and a beta of 0.62.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.04). The firm had revenue of $10.46 million for the quarter, compared to analysts' expectations of $15.61 million. Nektar Therapeutics had a negative net margin of 180.70% and a negative return on equity of 173.28%. During the same period in the prior year, the business posted ($0.18) earnings per share. As a group, equities research analysts forecast that Nektar Therapeutics will post -0.72 earnings per share for the current year.

Institutional Investors Weigh In On Nektar Therapeutics

Institutional investors have recently bought and sold shares of the company. Jane Street Group LLC lifted its stake in Nektar Therapeutics by 50.0% in the 3rd quarter. Jane Street Group LLC now owns 91,470 shares of the biopharmaceutical company's stock worth $119,000 after purchasing an additional 30,481 shares in the last quarter. Barclays PLC lifted its stake in Nektar Therapeutics by 96.1% in the 3rd quarter. Barclays PLC now owns 358,294 shares of the biopharmaceutical company's stock worth $466,000 after purchasing an additional 175,596 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Nektar Therapeutics by 197.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 913,300 shares of the biopharmaceutical company's stock worth $1,187,000 after purchasing an additional 606,057 shares in the last quarter. HB Wealth Management LLC lifted its stake in Nektar Therapeutics by 44.0% in the 4th quarter. HB Wealth Management LLC now owns 64,100 shares of the biopharmaceutical company's stock worth $60,000 after purchasing an additional 19,600 shares in the last quarter. Finally, SG Americas Securities LLC lifted its stake in Nektar Therapeutics by 12.2% in the 4th quarter. SG Americas Securities LLC now owns 107,318 shares of the biopharmaceutical company's stock worth $100,000 after purchasing an additional 11,681 shares in the last quarter. 75.88% of the stock is currently owned by institutional investors and hedge funds.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.